| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Regular Article |
a Departments of Obstetrics and Gynecology and Cell Biology, Duke University Medical Center, Durham, North Carolina 27710
ABSTRACT
2-Methoxyestradiol (2-ME) is an estradiol metabolite with antiangiogenic and antitumor activity. It is formed by granulosa cell (GC) catechol-O-methyltransferase activity and is present in the normal follicle at high concentrations. In this unique microenvironment, it may regulate selected cell types via autocrine and/or paracrine action. To assess the possibility that 2-ME or estradiol might exert differential mitotic and/or apoptotic effects on endothelial cells and GCs, we compared their actions on primary cultures of hormone- and/or growth factor-stimulated porcine GCs (pGCs) as well as two types of endothelial cells, primary cultures of porcine endothelial cells (pECs), and a spontaneously transformed rabbit endothelial vascular cell (REVC) line. The 2-ME, but not estradiol, dose dependently suppressed tritiated thymidine (3H-T) incorporation into epidermal growth factor (EGF)-stimulated REVCs and EGF/insulin (INS)-stimulated pECs. In contrast, 2-ME did not attenuate incorporation in FSH/INS-stimulated pGCs. It reduced incorporation by approximately 50% in EGF/INS-stimulated pGCs, indicating that responsiveness to 2-ME in normal cells can be modulated by hormone and growth factor treatment. Estradiol was not antimitotic to pGCs. As indicated by 4',6-diamido-2-phenylindole hydrochloride nuclear staining, estradiol was nonapoptotic in either cell type, and 2-ME significantly increased apoptosis of REVCs, but not of pGCs. In a cell migration assay, REVC movement was attenuated by 2-ME, but not by estradiol. In summary, the results show that antimitotic as well as proapoptotic responses to 2-ME vary with cell type and, in the case of pGC antimitotic activity, with the regulatory microenvironment. Thus, they provide a rationale for autocrine and/or paracrine action of 2-ME at its site of production in vivo, and they strongly support the concept of 2-ME as a candidate ovarian angiogenesis inhibitor.
First decision: 5 January 2001.
1 Supported in part by grants HD 11827 and T32 HD 07135 from the NICHD, DK 07012 from the NIDDK, the Andrew W. Mellon Foundation, and ACS-IRG-INMI58, an Institutional Research Grant Award to the Duke University Comprehensive Cancer Center.
2 Correspondence: David W. Schomberg, Box 3323, Duke University Medical Center, Durham, NC 27710. FAX: 919 681 6494; david.schomberg{at}duke.edu
This article has been cited by other articles:
|
|
 |
|
  S. Salih, X. Xu, T. D. Veenstra, A. J. Duleba, H. Fouad, M. Nagamani, and A. Al-Hendy Lower Levels of Urinary 2-Hydroxyestrogens in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3285 - 3291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Eichenlaub-Ritter, U. Winterscheidt, E. Vogt, Y. Shen, H.-R. Tinneberg, and R. Sorensen 2-Methoxyestradiol Induces Spindle Aberrations, Chromosome Congression Failure, and Nondisjunction in Mouse Oocytes Biol Reprod, May 1, 2007; 76(5): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Gruemmer, L Klein-Hitpass, and J Neulen Regulation of gene expression in endothelial cells: the role of human follicular fluid J. Mol. Endocrinol., February 1, 2005; 34(1): 37 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Lattanzi, C. B. Santos, M. D. Mudry, and J. L. Baranao Exposure of Bovine Oocytes to the Endogenous Metabolite 2-Methoxyestradiol During In Vitro Maturation Inhibits Early Embryonic Development Biol Reprod, December 1, 2003; 69(6): 1793 - 1800. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
